4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23) FY Earnings: $17.1 billion (earnings were $365 million FY23) ...

Highlights Launched Vision 2030Delivered Adjusted EBITDA margin of 19.1%Returned to positive packaging volume growth in second half of the yearAchieved Innovation Sales Growth of $205 millionExecuted ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but missing out on overall survival.

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...

The trial builds off the previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in patients with HNSCC.

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

"Millions of packages moved away from SurePost and the United States Postal Service and returned to UPS package cars this month, now being sorted and delivered by hardworking UPS Teamsters." ...

Rethinking Materials and Kraft Heinz are challenging start-ups worldwide to develop new and more sustainable packaging. The competition seeks flexible food packaging solutions that are either ...

Despite the lowered price target from $136 to $119 due to risks related to Keytruda’s loss-of-exclusivity and Medicare price caps, Graybosch remains optimistic about Merck’s ability to shift ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...